Literature DB >> 29769992

Advancing surveillance of antimicrobial resistance: Summary of the 2015 CIDSC Report.

K Amaratunga1,2, J Tarasuk1, L Tsegaye3, C P Archibald1.   

Abstract

BACKGROUND: Antimicrobials are essential for the treatment and control of infectious diseases and therefore, the development and spread of antimicrobial resistance (AMR) is a global health concern. It is recognized that robust AMR surveillance is necessary; however, current gaps in national surveillance programs need to be addressed to enable better evidence-informed program and policy decisions.
OBJECTIVE: To describe how an AMR Surveillance Task Group prioritized national AMR surveillance data requirements for high priority AMR organisms for human health in Canada and made recommendations on addressing the current data gaps.
METHODS: The 2015 AMR Surveillance Task Group examined the data requirements for previously identified first priority organisms and assessed whether the current system met, partially met or did not meet these requirements. Information was summarized into synopsis tables and a ranking process was used to prioritize the data requirements and develop specific recommendations to address the gaps.
RESULTS: First priority organisms identified for AMR surveillance are: Clostridium difficile, Extended-spectrum β-lactamase-producing organisms, Carbapenem-resistant organisms (Acinetobacter + Enterobacteriaceae species), Enterococcus species, Neisseria gonorrhoeae, Streptococcus pyogenes and S. pneumonaea, Salmonella species, Staphylococcus aureus, Mycobacterium tuberculosis and Campylobacter species. For these organisms, there were 19 high priority data requirements identified: 10 of these requirements were met by the current surveillance systems, seven were partially met and two were unmet. For the two high priority data metrics in the community setting, the Task Group recommended conducting a point-prevalence community-based study (i.e., every five years) to follow infection rates of C. difficile infection, and community level antibiogram data on an annual basis for susceptibility data for Enterobacteriaceae species (E. coli and Klebsiella) causing genito-urinary infections. There were eight medium priority data requirements identified: one requirement was met by the current surveillance system, five were partially met and two were unmet. The medium priority unmet data requirements included susceptibility of infection isolates for C. difficile (diarrheal disease) and infection rates for Enterobacteriaceae species causing genito-urinary tract infections in community settings. It was noted that the feasibility of obtaining this medium priority in data in the community setting was low. The Task Group identified bloodstream infections as the top priority site of infection for AMR surveillance in the health care setting given the high morbidity and mortality associated with bloodstream infections. The importance of collecting susceptibility data on N. gonorrhoeae in the community was underscored given the rise in resistance and that the current surveillance system only partially collects this data. The Task Group recommended that a review of the national AMR surveillance data requirement priorities should occur on an ongoing basis and when new issues emerge.
CONCLUSION: While current national surveillance programs either capture or partially capture many of the identified data requirements for first priority organisms, several gaps still remain, especially in community settings. A national review of the recommendations of the Task Group is underway.

Entities:  

Year:  2016        PMID: 29769992      PMCID: PMC5757739          DOI: 10.14745/ccdr.v42i11a03

Source DB:  PubMed          Journal:  Can Commun Dis Rep        ISSN: 1188-4169


  6 in total

1.  Summary of the Federal Action Plan on Antimicrobial Resistance and Use in Canada.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2015-06-18

2.  Antibiotic purchasing by Canadian hospitals, 2007-2011.

Authors:  R Finley
Journal:  Can Commun Dis Rep       Date:  2014-11-07

3.  Antimicrobial resistance surveillance in Canadian hospitals, 2007-2012.

Authors:  D Gravel; C P Archibald; L Pelude; M Mulvey; G Golding
Journal:  Can Commun Dis Rep       Date:  2014-11-07

4.  Canadian integrated program for antimicrobial resistance surveillance: Retail food highlights, 2003-2012.

Authors:  B P Avery; E J Parmley; R J Reid-Smith; D Daignault; R L Finley; R J Irwin
Journal:  Can Commun Dis Rep       Date:  2014-11-07

5.  Antimicrobial use and antimicrobial resistance trends in Canada: 2014.

Authors:  M Ebrahim; D Gravel; C Thabet; K Abdesselam; S Paramalingam; C Hyson
Journal:  Can Commun Dis Rep       Date:  2016-11-03

6.  Antibiotic recommendations of office-based physicians, 2007-2011.

Authors:  R Finley
Journal:  Can Commun Dis Rep       Date:  2014-11-07
  6 in total
  5 in total

1.  Emerging risk of untreatable gonorrhea and what to do about it.

Authors: 
Journal:  Can Fam Physician       Date:  2017-03       Impact factor: 3.275

2.  How is an international public health threat advanced in Canada? The case of antimicrobial resistance.

Authors:  L Tsegaye; P Huston; R Milliken; K Hanniman; C Nesbeth; L Noad
Journal:  Can Commun Dis Rep       Date:  2016-11-03

3.  Epidemiology of Clostridioides difficile infection in Canada: A six-year review to support vaccine decision-making.

Authors:  Y Xia; M C Tunis; C Frenette; K Katz; K Amaratunga; S Rhodenizer Rose; A House; C Quach
Journal:  Can Commun Dis Rep       Date:  2019-07-04

Review 4.  Antimalarial Drug Resistance and Implications for the WHO Global Technical Strategy.

Authors:  Matthew M Ippolito; Kara A Moser; Jean-Bertin Bukasa Kabuya; Clark Cunningham; Jonathan J Juliano
Journal:  Curr Epidemiol Rep       Date:  2021-03-14

5.  Automating the Generation of Antimicrobial Resistance Surveillance Reports: Proof-of-Concept Study Involving Seven Hospitals in Seven Countries.

Authors:  Cherry Lim; Thyl Miliya; Vilada Chansamouth; Myint Thazin Aung; Abhilasha Karkey; Prapit Teparrukkul; Batra Rahul; Nguyen Phu Huong Lan; John Stelling; Paul Turner; Elizabeth Ashley; H Rogier van Doorn; Htet Naing Lin; Clare Ling; Soawapak Hinjoy; Sopon Iamsirithaworn; Susanna Dunachie; Tri Wangrangsimakul; Viriya Hantrakun; William Schilling; Lam Minh Yen; Le Van Tan; Htay Htay Hlaing; Mayfong Mayxay; Manivanh Vongsouvath; Buddha Basnyat; Jonathan Edgeworth; Sharon J Peacock; Guy Thwaites; Nicholas Pj Day; Ben S Cooper; Direk Limmathurotsakul
Journal:  J Med Internet Res       Date:  2020-10-02       Impact factor: 5.428

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.